Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- MONDO_0001087 label "Schizotypal personality disorder" assertion.
- association label "There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial." assertion.
- context label "Children and adolescents" assertion.
- MONDO_0005414 label "Schizophrenia" assertion.
- context label "Children and adolescents" assertion.
- association label "Clozapine has a more significant impact for the treatment of positive psychotic symptoms as compared to negative symptoms and has been shown to be effective for aggression, suicidal behaviors, obsessive–compulsive disorder, and autism spectrum disorder." assertion.
- context label "Adults" assertion.
- association label "This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system." assertion.
- context label "Adults" assertion.
- association label "Off-label and novel treatments continue to be considered for more refractory and disabling cases of PTSD." assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- association label "The nicotinic-acetylcholine receptor (nAchR)- antagonist mecamylanine has been found to reduce the stimulus produced by ethanol in human lab studies. The nAchR-antagonist varenicline has also displayed positive effect in reducing alcohol consumption in multiple clinical trials. In this 12- week double-blind trial, participants (n 1⁄4 126) were randomized to either mecamylamine (10 mg daily) or placebo. No medication effect was found for reducing heavy drinking days (HDD) or alcohol craving. Smoking status had no effect on the results. The authors suggest that broad-spectrum nAchR-antagonists may not be beneficial in treat- ing AUD" assertion.
- context label "Adults" assertion.
- association label "These findings suggest that if ketamine is to find a place as an off-label treatment for depression and suicidality in mainstream psychiatry, researchers should study the safety, efficacy, and optimization of oral ketamine. Intravenous and intranasal routes may be monetarily more promising, but the oral route could be of greatest service." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual's quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer's disease (AD) or Parkinson's disease (PD). In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Quetiapine (see supplement) is also commonly used in (off-label) for NPS in AD." assertion.
- context label "Adults" assertion.
- HP_0000709 label "Psychosis" assertion.
- HP_0000709 label "Psychosis" assertion.
- HP_0000709 label "Psychosis" assertion.
- HP_0000709 label "Psychosis" assertion.
- association label "A 30-year-old insomniac, an off-label user of quetiapine, presented with blurring of central vision, eventually diagnosed as central serous chorioretinopathy." assertion.
- cohort label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- association label "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “history of migraines and depression, both well controlled on bupropion and amitriptyline”" assertion.
- association label "Clinician's annotation: “foot pain—chronic, not neuropathy apparently, will give trial of nortrip in case”" assertion.
- context label "Adults" assertion.
- HP_0025238 label "foot pain" assertion.
- association label "Clinician's annotation: “Has been taking increased dose of nortriptyline since last visit and notes much less pain radiating to leg”" assertion.
- context label "Adults" assertion.
- HP_0012531 label "pain" assertion.
- association label "Clinician's annotation: “Pt was told to continue Lexapro. RX options for her constipation were reviewed”" assertion.
- context label "Adults" assertion.
- MONDO_0002203 label "constipation disorder" assertion.
- association label "Cyclobenzaprine is frequently used off-label in fibromyalgia and is associated with improved pain, sleep, and fatigue in several studies." assertion.
- context label "adults" assertion.
- association label "Guidelines recommend the use of neuromodulators in patients with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics; however, there is a lack of data from randomised controlled trials supporting their use." assertion.
- context label "adults" assertion.
- MONDO_0002268 label "Dyspepsia" assertion.
- association label "Tension-type headache (TTH) is the most common primary headache disorder, with a worldwide lifetime prevalence of 46% to 78%. (...) Amitriptyline is recommended as a first-line drug for prophylaxis. (This is an off-label use of amitriptyline)." assertion.
- context label "adults" assertion.
- HP_0012228 label "Tension-type headache" assertion.
- context label "adults" assertion.
- association label "Off-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms is controversial, not least because the evidence base for maintenance treatment with repeated ketamine administration is currently weak. Ketamine is also a drug of misuse, which has raised concerns regarding the target population." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "Two other sedating antidepressants, mirtazapine and trimipramine, are commonly used off-label for the treatment of ID without clear recommendations by any of the guidelines." assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- association label ""edex (r) in men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia [see WARNINGS for the treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as cavernosal fibrosis or Peyronie's disease [see PRECAUTIONS in men with penile implants"" assertion.
- association label ""GVOKE is contraindicated in patients with: Pheochromocytoma [ see Warnings and Precautions ( 5.1 Insulinoma [ see Warnings and Precautions ( 5.2 Known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [ see Warnings and Precautions ( 5.3 Pheochromocytoma ( 4 Insulinoma ( 4 Known hypersensitivity to glucagon or to any of the excipients ( 4"" assertion.
- association label ""The use of nortriptyline hydrochloride or other tricyclic antidepressants concurrently with a monoamine oxidase (MAO) inhibitor is contraindicated. Hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. It is advisable to have discontinued the MAO inhibitor for at least two weeks before treatment with nortriptyline hydrochloride is started. Patients hypersensitive to nortriptyline hydrochloride should not be given the drug. Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."" assertion.
- association label "Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide." assertion.
- association label ""Danazol capsules should not be administered to patients with: Undiagnosed abnormal genital bleeding. Markedly impaired hepatic, renal, or cardiac function. Pregnancy (see ). WARNINGS Breast feeding. Porphyria - danazol can induce ALA synthetase activity and hence porphyrin metabolism. Androgen-dependent tumor. Active thrombosis or thromboembolic disease and history of such events. Hypersensitivity to danazol."" assertion.